For Generics, A Victory Lap – And A Warning – On Drug Shortages
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
You may also be interested in...
As the response to another wave of COVID-19 infections continues, fill rates of critical medicines such as methylprednisolone are dropping. But experts say the answer is not to concentrate manufacturing in US facilities, which could lead to further risks if US supply is disrupted.
Pink Sheet Podcast: Election Fallout, IRA Impacting Product Development, Updated US FDA Expanded Access Policy
Pink Sheet reporters and editor discuss the impact of the midterm elections, the Inflation Reduction Act’s effects on drug development, and adjustments to FDA expanded access guidance.
Pink Sheet Podcast: Makena Withdrawal Hearing Nears, In-Person Meetings At US FDA, User Fees Released
Pink Sheet reporters and editor discuss new developments in the Makena withdrawal case, FDA taking small steps toward resuming in-person meetings at its headquarters, and the agency finally releasing the FY 2023 user fee rates.